Valeant Pharmaceuticals International (NYSE:VRX) announced that it has enrolled the first patient in its Phase 2 clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles. “We are eager to investigate whether retigabine, our new novel potassium channel opener, will be effective in treating neuropathic pain,” said Timothy C. Tyson, president and chief executive officer. [click link for full article]